Updated Outpatient Treatment Guidance for Covid-19 in Symptomatic Adults

Clinical Takeaway

: Revised guidelines reinforce the use of nirmatrelvir–ritonavir and molnupiravir in adults at high risk for severe disease.

An overview of the Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points from the American College of Physicians (Version 3)

Background

This clinical practice guideline and rapid review update recommendations for antiviral treatment of confirmed Covid-19, incorporating seven new studies published since 2023.

Key Points

The authors recommend nirmatrelvir–ritonavir or molnupiravir for outpatients with Covid-19 who are within 5 days of symptom onset and at high risk for severe disease. “High-risk” is loosely defined based on age and the presence of a range of chronic conditions, including lung disease, diabetes, and obesity.
Both nirmatrelvir–ritonavir and molnupiravir appear to shorten symptom duration.
Nir…

Reviewing Author

Sara Turbow, M.D., M.P.H.

Disclosures

RoyaltiesHovde Dassow & Deets

Grant/Research SupportNational Institute on Aging / National Institutes of Health; Health Resources and Services Administration; Macy Foundation; Eli Lilly

Editorial BoardsPreventing Chronic Disease